OEBERGS contributes to malaria research

Every minute an African child is killed by malaria.

Professor Mats Wahlgren at Karolinska Institutet, Stockholm, has together with Dilaforette AB developed a new treatment for severe malaria, SevuparinTM. This medicine prevents and reverses the ability of the parasitized red blood cells to block blood vessels. SevuparinTM is ready for a phase II clinical trial, i.e. testing it on children in Africa. Professor Wahlgren, member of the Nobel Committee for Physiology or Medicine 2015, wants to start a “Malaria Foundation Sweden” to finance such a phase II study. OEBERGS has, on a pro bono basis, been given the assignment to structure the foundation.